Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Medtronic
McKesson
Moodys
Mallinckrodt

Last Updated: October 24, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for AZD-1480

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug AZD-1480: Sponsors, patents, clinical trial progress

AZD-1480 is an investigational drug.

There have been 30 clinical trials for AZD-1480. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2010.

The most common disease conditions in clinical trials are Adenocarcinoma, Ovarian Neoplasms, and Small Cell Lung Carcinoma. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Samsung Medical Center.

There are ten US patents protecting this investigational drug and seventy-seven international patents.

Recent Clinical Trials for AZD-1480
TitleSponsorPhase
Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerNational Cancer Institute (NCI)Phase 2
Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerM.D. Anderson Cancer CenterPhase 2
Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian CancerAstraZenecaPhase 2

See all AZD-1480 clinical trials

Clinical Trial Summary for AZD-1480

Top disease conditions for AZD-1480
Top clinical trial sponsors for AZD-1480

See all AZD-1480 clinical trials

US Patents for AZD-1480

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AZD-1480   Start Trial Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections EMORY UNIVERSITY (Atlanta, GA)   Start Trial
AZD-1480   Start Trial Compounds and methods for inhibiting JAK Dizal (Jiangsu) Pharmaceutical Co., Ltd. (Wuxi, Jiangsu Province, CN)   Start Trial
AZD-1480   Start Trial Formylated N-heterocyclic derivatives as FGFR4 inhibitors NOVARTIS AG (Basel, CH)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Dow
Boehringer Ingelheim
AstraZeneca
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.